Simon Clark has joined Polpharma as vice-president of the management board and chief commercial officer...
Polpharma has announced that the Main Pharmaceutical Inspectorate (MPI) have completed two inspections at its active pharmaceutical ingredients (API) plant in Poland.
Both inspections finished with positive results, and the inspectors will recommend the issue of good manufacturing practice (GMP) certificates for all the substances evaluated.
It was further acknowledged that the API Plant meets GMP requirements, and the certificate makes it possible to sell products worldwide.
This is the best confirmation that Polpharma delivers high-quality products.
In September, the following active substances were accepted by the MPI:
- Bazedoxifene Acetate
- Aripiprazole Monohydrate
- Tolterodine tartrate
In October, MPI approved another eight active substances:
- Alendronate sodium trihydrate
- Saxagliptin monohydrate
- Zolendronic acid monohydrate
This white paper outlines Polpharma B2B's finished dosage formulations (FDF) that are currently under development. Products...
Polpharma B2B is a significant European active pharmaceutical ingredient (API) producer with current good manufacturing...
Polpharma B2B's team of experts will be pleased to meet you at the CPhI Worldwide...